Cipla’s manufacturing facility at Pithampur, Indore receives “Official Action Indicated” classification from U.S. FDA for not meeting regulatory requirements; OAI status may delay/hold product pending approval

Pharmaceutical tablets and capsules are arranged on table in photo illustration

BENGALURU, Aug 5 (MeelBijendra) – Late on Saturday night, Indian drugmaker Cipla received an ‘Official Action Indicated’ (OAI) classification from the United States Food and Drug Administration’s (USFDA) inspection carried out in February 2023 at Cipla’s manufacturing facility in Pithampur, Indore. The United States Food and Drug Administration (USFDA), an agency of the United States … Read more